Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby R, Firth L, Lewis E. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby R, Firth L, Lewis E
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Therapy that keeps blood glucose levels as close to normal as possible in type 1 diabetics, reduces damage to the kidneys by 35-56%. Experts believe that these results can be…  
  • Blood pressure control reduces the risk of cardiovascular disease (heart disease or stroke) among people with diabetes by 33% to 50%, and the risk of microvascular complications (eye, kidney, and…  
  • The use of insulin pumps create net cost savings, including $5886 annually per person affected and $34.9 million in increased tax revenue  
  • Participants in a diabetes self-management education program for Medicaid recipients, consisting of a 60 minute initial individual assessment of needs, followed by 12 hours of group education on nutrition and…  
  • For every 10 mmHg reduction in systolic blood pressure, the risk of diabetic complications is reduced by 12%.